CUA 2017: What’s New in Patient-Reported Outcomes Following Treatment for Localized Prostate Cancer?
Toronto, Ontario (UroToday.com) Dr. David Penson, the Paul V. Hamilton, M.D. and Virginia E. Howd Chair in Urologic Oncology and Professor of Urologic Surgery and Medicine at Vanderbilt University Medical Center, gave an excellent talk highlighting the status of patient-reported outcomes (PROs) following treatment for localized prostate cancer (PCa).
CUA 2017: Four vs. 10 Months of Induction Androgen-Deprivation Therapy for Intermittent Therapy (the FIT trial): A Prospective Canadian Urology Research Consortium Randomized Trial
Toronto, Ontario (UroToday.com) Men with metastatic prostate cancer (PCa) are placed on androgen-deprivation therapy (ADT) for control of their disease. However, long-term ADT can have consequences on men’s health, including risk of osteoporosis and heart disease, along with the adverse events associated with it.
CUA 2017: A Propensity Score Analysis of Radical Cystectomy vs. Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic
Toronto, Ontario (UroToday.com) Muscle-invasive bladder cancer (MIBC) drives the mortality of bladder cancer as a disease, and until now, the only level 1 evidence for its management supports the use of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC). However, NAC + RC is a highly morbid intervention, particularly in the elderly population that entails the bladder cancer patient pool.
CUA 2017: Safety of Minimizing Intensity of Followup on Active Surveillance for Clinical Stage I Testicular Germ Cell Tumors
Toronto, Ontario (UroToday.com) Active surveillance of stage 1 testicular germ cell tumors remains a standard of care, but the AS regimen continues to be modified and improved with experience. The Princess Margaret Cancer Centre (PMCC) experience with active surveillance has a long history, and began recommending a non-risk adapted active surveillance protocol for all clinical stage I (CSI) testicular germ cell tumors (TGCT) in 1981.
CUA 2017: Long-Term Incidence of Venous Thromboembolic Events Following cystectomy: A Population-Based Analysis
Toronto, Ontario (UroToday.com) Cancer and immobility both contribute to the development of venous thromboembolic events (VTE), including pulmonary embolism and deep vein thrombosis. As such, patients undergoing radical cystectomy for bladder cancer are at elevated risk. Dr. Diane Magee presented a study assessing the long-term incidence of VTE among all patients undergoing radical cystectomy in the province of Ontario.
CUA 2017: Radical Cystectomy After Prior Partial Cystectomy for Urothelial Carcinoma: Perioperative and Oncological Outcomes
Toronto, Ontario (UroToday.com) Up to 50% of patients treated with partial cystectomy (PC) have been reported to require radical cystectomy (RC) due to local disease recurrence. The outcomes for these patients have not been well-described to date. Dr. Mason Ross presented a study evaluating outcomes of patients undergoing RC after PC for urothelial carcinoma (UC).
CUA 2017: Creation of a Prediction Tool for Renal Function After Partial and Radical Nephrectomy: Personalizing Decision-Making for Renal Cancer Surgery
Toronto, Ontario (UroToday.com) This study aimed to create a preoperative prediction tool for renal function outcomes at various time points following partial nephrectomy (PN) and radical nephrectomy (RN) in order to help guide the choice of surgical approach.